Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)

Jacques H. Grosset, Nicole C. Ammerman

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Evaluation of: Diacon AH, Dawson R, Von Groote-Bidlingmaier F et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 57(5), 2199-2203 (2013). During the past decade considerable efforts have been made to develop and register new anti-TB drugs, making them available for patients in need. Bedaquiline (BDQ), approved by the US FDA in December 2012, is the first new anti-TB drug available for treatment of this disease since rifampicin became available in 1967. BDQ has the peculiarity of being a drug with a very long half-life and potent antimicrobial activity that becomes noticeable only after the first 4 days of treatment. Consequently, Diacon et al. have conducted a 14-day dose-ranging study aimed at assessing the early bactericidal activity of BDQ in TB patients who received loading doses of the drug during the first 2 days of treatment. The loading doses partially overcame the delayed antimicrobial activity only in patients treated daily with as much as 400 mg.

Original languageEnglish (US)
Pages (from-to)649-651
Number of pages3
JournalExpert Review of Anti-Infective Therapy
Issue number7
StatePublished - Jul 2013


  • tuberculosis treatment

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases


Dive into the research topics of 'Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)'. Together they form a unique fingerprint.

Cite this